The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Subscribe To Our Newsletter & Stay Updated
